Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats

Journal of Steroid Biochemistry and Molecular Biology

Volumn 94, Issue 5, 2005, Pages 489-498

  Kisanga, Elton Richard ^a   Haugan Moi, Line L ^a,b   Gjerde, Jennifer ^a,b   Mellgren, Gunnar ^a,b   Lien, Ernst A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

CYP; Cytochrome P450; Enzyme induction; Pharmacokinetics; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450; CYTOCHROME P450 3A18; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLITE; LIVER ENZYME; MESSENGER RNA; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INDUCTION; ENZYME METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MEASUREMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TISSUE LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUCURONOSYLTRANSFERASE; INFUSIONS, PARENTERAL; LIVER; OXYGENASES; RATS; RATS, NUDE; RNA, MESSENGER; TAMOXIFEN;

ANIMALIA;

EID: 18144404156     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.12.037     Document Type: Article

References (56)

1. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90 1998 1371 1388
2. J.I. MacGregor, and V.C. Jordan Basic guide to the mechanisms of antiestrogen action Pharmacol. Rev. 50 1998 151 196
3. J. Cuzick, J. Forbes, R. Edwards, M. Baum, S. Cawthorn, A. Coates, A. Hamed, A. Howell, and T. Powles First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial Lancet 360 2002 817 824
4. U. Veronesi, P. Maisonneuve, A. Costa, V. Sacchini, C. Maltoni, C. Robertson, N. Rotmensz, and P. Boyle Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study Lancet 352 1998 93 97
5. J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, S. Ashley, and P. Boyle Overview of the main outcomes in breast-cancer prevention trials Lancet 361 2003 296 300
6. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J. Pharmacol. Exp. Ther. 270 1994 414 423
7. S. Rendic, and F.J. Di Carlo Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors Drug Metab. Rev. 29 1997 413 580
8. K.E. Thummel, D.D. Shen, T.D. Podoll, K.L. Kunze, W.F. Trager, P.S. Hartwell, V.A. Raisys, C.L. Marsh, J.P. McVicar, and D.M. Barr Use of midazolam as a human cytochrome P4503A probe: I. In vitro-in vivo correlations in liver transplant patients J. Pharmacol. Exp. Ther. 271 1994 549 556
9. M. Ingelman-Sundberg, M. Oscarson, and R.A. McLellan Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment Trends Pharmacol. Sci. 20 1999 342 349
10. A. Mahnke, D. Strotkamp, P.H. Roos, W.G. Hanstein, G.G. Chabot, and P. Nef Expression and inducibility of cytochrome P4503A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver Arch. Biochem. Biophys. 337 1997 62 68
11. K. Nagata, M. Ogino, M. Shimada, M. Miyata, F.J. Gonzalez, and Y. Yamazoe Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6betaB) and characterization of the recombinant protein Arch. Biochem. Biophys. 362 1999 242 253
12. J.K. Coller, N. Krebsfaenger, K. Klein, R. Wolbold, A. Nüssler, P. Neuhaus, U.M. Zanger, M. Eichelbaum, and T.E. Mürdter Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity Br. J. Clin. Pharmacol. 57 2004 105 111
13. T. Kasahara, M. Hashiba, T. Harada, and M. Degawa Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats Carcinogenesis 23 2002 491 498
14. M.M. Cotreau, L.L. von Moltke, J.S. Harmatz, and D.J. Greenblatt Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen Pharmacology 63 2001 210 219
15. P.B. Desai, S.C. Nallani, R.S. Sane, L.B. Moore, B.J. Goodwin, D.J. Buckley, and A.R. Buckley Induction of cytochrome P4503A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen Drug Metab. Dispos. 30 2002 608 612
16. H.K. Crewe, S.W. Ellis, M.S. Lennard, and G.T. Tucker Variable contribution of cytochromes P4502D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes Biochem. Pharmacol. 53 1997 171 178
17. J. Venhorst, A.M. ter Laak, J.N. Commandeur, Y. Funae, T. Hiroi, and N.P. Vermeulen Homology modeling of rat and human cytochrome P4502D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities J. Med. Chem. 46 2003 74 86
18. D.J. Boocock, K. Brown, A.H. Gibbs, E. Sanchez, K.W. Turteltaub, and I.N.H. White Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA Carcinogenesis 23 2002 1897 1901
19. J.K. Coller Oxidative metabolism of tamoxifen to Z-4-hydroxytamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies Clini. Exp. Pharmacol. Physiol. 30 2003 845 848
20. S.S. Dehal, and D. Kupfer CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver Cancer Res. 57 1997 3402 3406
21. C. Mani, R. Pearce, A. Parkinson, and D. Kupfer Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes Carcinogenesis 15 1994 2715 2720
22. C. Mani, H.V. Gelboin, S.S. Park, R. Pearce, A. Parkinson, and D. Kupfer Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P450-catalyzed N-demethylation and 4-hydroxylation Drug Metab. Dispos. 21 1993 645 656
23. C. Mani, E. Hodgson, and D. Kupfer Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation Drug Metab. Dispos. 21 1993 657 661
24. T. Nishiyama, K. Ogura, H. Nakano, T. Ohnuma, T. Kaku, A. Hiratsuka, K. Muro, and T. Watabe Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases Biochem. Pharmacol. 63 2002 1817 1830
25. S. Shibutani, P.M. Shaw, N. Suzuki, L. Dasaradhi, M.W. Duffel, and I. Terashima Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts Carcinogenesis 19 1998 2007 2011
26. A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E.R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, M.T. Sandri, G. Pelosi, A. Luini, A. Goldhirsch, E.A. Lien, and U. Veronesi A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers J. Natl. Cancer Inst. 95 2003 779 790
27. F. Peyrade, M. Frenay, M.C. Etienne, F. Ruch, C. Guillemare, E. Francois, M. Namer, J.M. Ferrero, and G. Milano Age-related difference in tamoxifen disposition Clin. Pharmacol. Ther. 59 1996 401 410
28. B. Fisher, J.P. Costantino, C.K. Redmond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86 1994 527 537
29. L.E. Rutqvist, H. Johansson, T. Signomklao, U. Johansson, T. Fornander, and N. Wilking Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group J. Natl. Cancer Inst. 87 1995 645 651
30. E.R. Kisanga, J. Gjerde, J. Schjøtt, G. Mellgren, and E.A. Lien Tamoxifen administration and metabolism in nude mice and nude rats J. Steroid Biochem. Mol. Biol. 84 2003 361 367
31. E.A. Lien, P.M. Ueland, E. Solheim, and S. Kvinnsland Determination of tamoxifen and four metabolites in serum by low-dispersion liquid chromatography Clin. Chem. 33 1987 1608 1614
32. E.A. Lien, E. Solheim, and P.M. Ueland Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment Cancer Res. 51 1991 4837 4844
33. Applied biosystems, Subject: Relative quantitation of gene expression, User Bull. (1997) 1-36.
34. T. Hiroi, S. Imaoka, T. Chow, and Y. Funae Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR Biochim. Biophys. Acta 1380 1998 305 312
35. S. Maiti, and G. Chen Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine Drug Metab. Dispos. 31 2003 637 644
36. E.F. Nuwaysir, Y.P. Dragan, C.R. Jefcoate, V.C. Jordan, and H.C. Pitot Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver Cancer Res. 55 1995 1780 1786
37. E.F. Nuwaysir, D.A. Daggett, V.C. Jordan, and H.C. Pitot Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen Cancer Res. 56 1996 3704 3710
38. E.T. Hellriegel, G.A. Matwyshyn, P. Fei, K.H. Dragnev, R.W. Nims, R.A. Lubet, and A.N. Kong Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver Biochem. Pharmacol. 52 1996 1561 1568
39. A. Kärki, E. Mäntylä, Y. Hirsimäki, S. Karlsson, S. Toikkanen, and P. Hirsimäki Comparison of the effects of tamoxifen and toremifene on rat hepatocarcinogenesis Arch. Toxicol. 74 2000 249 256
40. G.A. Dannan, F.P. Guengerich, and D.J. Waxman Hormonal regulation of rat liver microsomal enzymes. Role of gonadal steroids in programming, maintenance, and suppression of delta 4-steroid 5 alpha-reductase, flavin-containing monooxygenase, and sex-specific cytochromes P-450 J. Biol. Chem. 261 1986 10728 10735
41. C.K. Lim, Z.X. Yuan, J.H. Lamb, I.N.H. White, F. De Matteis, and L.L. Smith A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes Carcinogenesis 15 1994 589 593
42. S.J. Carter, X.F. Li, J.R. Mackey, S. Modi, J. Hanson, and N.J. Dovichi Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry Electrophoresis 22 2001 2730 2736
43. G.K. Poon, Y.C. Chui, R. McCague, P.E. Lonning, R. Feng, M.G. Rowlands, and M. Jarman Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients Drug Metab. Dispos. 21 1993 1119 1124
44. D.J. Boocock, J.L. Maggs, K. Brown, I.N.H. White, and B.K. Park Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts Carcinogenesis 21 2000 1851 1858
45. S. Dauvois, R. White, and M.G. Parker The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling J. Cell Sci. 106 1993 1377 1388
46. I.N. White Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans Curr. Drug. Metab. 4 2003 223 239
47. J.A. Bailey, and K.P. Nephew Strain differences in tamoxifen sensitivity of Sprague-Dawley and Fischer 344 rats Anticancer Drugs 13 2002 939 947
48. L.A. Stanley, P. Carthew, R. Davies, F. Higginson, E. Martin, and J.A. Styles Delayed effects of tamoxifen in hepatocarcinogenesis-resistant Fischer 344 rats as compared with susceptible strains Cancer Lett. 171 2001 27 35
49. C. Handschin, and U.A. Meyer Induction of drug metabolism: the role of nuclear receptors Pharmacol. Rev. 55 2003 649 673
50. K. Swales, N. Plant, A. Ayrton, S. Hood, and G. Gibson Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells Xenobiotica 33 2003 703 716
51. X.J. Zhao, D.R. Jones, Y.H. Wang, S.W. Grimm, and S.D. Hall Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites Xenobiotica 32 2002 863 878
52. V. Lattard, J. Lachuer, T. Buronfosse, F. Garnier, and E. Benoit Physiological factors affecting the expression of FMO1 and FMO3 in the rat liver and kidney Biochem. Pharmacol. 63 2002 1453 1464
53. M. Dowsett, C. Pfister, S.R. Johnston, D.W. Miles, S.J. Houston, J.A. Verbeek, H. Gundacker, A. Sioufi, and I.E. Smith Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer Clin. Cancer Res. 5 1999 2338 2343
54. M. Dowsett, J. Cuzick, A. Howell, and I. Jackson Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial Br. J. Cancer 85 2001 317 324
55. E.A. Lien, G. Anker, P.E. Lonning, E. Solheim, and P.M. Ueland Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide Cancer Res. 50 1990 5851 5857
56. E.R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E.A. Lien Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial Clin. Cancer Res. 10 2004 2336 2343